3-氨基-5-氯甲基吡啶 | 89639-36-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氨基-5-氯甲基吡啶
• 中文别名: 3-氨基-5-氯-2-甲基吡啶
• 英文名称: 5-chloro-2-methylpyridin-3-amine
• CAS: 89639-36-1
• 化学式: C₆H₇ClN₂
• 分子量: 142.588
• InChiKey: ZZVRTFCAHUHTDJ-UHFFFAOYSA-N

物化性质

• 沸点：
  270.3±35.0 °C(Predicted)
• 密度：
  1.260±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Amino-5-chloropicoline
Synonyms: 5-Chloro-2-methylpyridin-3-amine; 3-Amino-5-chloro-2-methylpyridine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Amino-5-chloropicoline
CAS number: 89639-36-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H7ClN2
Molecular weight: 142.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基-5-氯甲基吡啶 在 硫酸 、 potassium carbonate 、 sodium nitrite 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.83h， 生成 methyl 5-{[(5-chloro-2-methylpyridin-3-yl)oxy]methyl}thiophene-2-carboxylate
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS AS WIP1 INHIBITORS
  [FR] NOUVEAUX COMPOSÉS EN TANT QU'INHIBITEURS DE WIP1

  摘要：

  本发明涉及酰化丙氨酸衍生物用于调节WIP1活性，特别是抑制其活性。适当地，本发明涉及酰化丙氨酸衍生物在癌症治疗中的应用。

  公开号：

  WO2012149102A1
• 作为产物：
  描述：

  2,5-二氯-3-硝基吡啶 在 tin(II) chloride dihdyrate 、 sodium hydride 作用下， 以 四氢呋喃 、 乙酸乙酯 、 mineral oil 为溶剂， 反应 19.33h， 生成 3-氨基-5-氯甲基吡啶
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS AS WIP1 INHIBITORS
  [FR] NOUVEAUX COMPOSÉS EN TANT QU'INHIBITEURS DE WIP1

  摘要：

  本发明涉及酰化丙氨酸衍生物用于调节WIP1活性，特别是抑制其活性。适当地，本发明涉及酰化丙氨酸衍生物在癌症治疗中的应用。

  公开号：

  WO2012149102A1

文献信息

• [EN] SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP)<br/>[FR] PETITES MOLÉCULES INHIBITRICES DU PORE DE TRANSITION DE PERMÉABILITÉ MITOCHONDRIALE (MTPTP)
  申请人：UNIV KANSAS

  公开号：WO2016073633A1

  公开（公告）日：2016-05-12

  The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.

  目前的技术涉及到本文描述的任一式I、II、IIa、III、IV和/或V的化合物，以及它们的互变异构体和/或药用盐、组合物以及使用方法。
• Discovery, Synthesis, and Optimization of Diarylisoxazole-3-carboxamides as Potent Inhibitors of the Mitochondrial Permeability Transition Pore
  作者：Sudeshna Roy、Justina Šileikytė、Marco Schiavone、Benjamin Neuenswander、Francesco Argenton、Jeffrey Aubé、Michael P. Hedrick、Thomas D. Y. Chung、Michael A. Forte、Paolo Bernardi、Frank J. Schoenen

  DOI：10.1002/cmdc.201500284

  日期：2015.10

  activity against mitochondrial swelling (EC50<0.39 μM) and showed no interference on the inner mitochondrial membrane potential (rhodamine 123 uptake EC50>100 μM). This enabled the construction of a series of picomolar mtPTP inhibitors that also potently increase the calcium retention capacity of the mitochondria. Finally, the therapeutic potential and in vivo efficacy of one of the most potent analogues

  线粒体通透性转换孔（mtPTP）是一种需要Ca 2+的巨型通道，在病理条件下会导致Ca 2+释放失调和线粒体功能障碍，最终导致细胞死亡。尽管 mtPTP 是许多人类病理的潜在治疗靶点，但其作为药物靶点的潜力目前尚未实现。在这里，我们描述了围绕命中1、5- (3-羟基苯基) -N- (3,4,5-三甲氧基苯基)异恶唑-3-甲酰胺发起的优化工作，发现其对线粒体肿胀具有良好的抑制活性 (EC 50 < 0.39微米) 并显示对线粒体内膜电位没有干扰（罗丹明 123 摄取 EC 50 >100 μ M）。这使得构建一系列皮摩尔 mtPTP 抑制剂成为可能，这些抑制剂也有效地增加了线粒体的钙保留能力。最后，最有效的类似物之一N- (3-氯-2-甲基苯基)-5-(4-氟-3-羟基苯基)异恶唑-3-甲酰胺 ( 60 )的治疗潜力和体内功效是在 VI 型胶原蛋白先天性肌营养不良的生物学相关斑马鱼模型中得到验证。
• [EN] IMIDAZOPYRROLIDINONE COMPOUNDS<br/>[FR] COMPOSÉS IMIDAZOPYRROLIDINONE
  申请人：NOVARTIS AG

  公开号：WO2013111105A1

  公开（公告）日：2013-08-01

  The invention relates to compounds of formula (I): (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

  这项发明涉及式(I)的化合物：(I)如本文所述，包括这种化合物的药物制剂，以及在治疗由MDM2和/或MDM4活性介导的疾病或疾病中使用这种化合物的用途和方法，以及包含这种化合物的组合物。
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20190169166A1

  公开（公告）日：2019-06-06

  Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

  提供的是一种可能具有GCN2抑制作用的杂环化合物，预计可用于预防或治疗与GCN2相关的疾病，包括癌症等。一种由以下式（I）表示的化合物： 其中每个符号如描述中所述，或其盐。
• PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
  申请人：Incyte Corporation

  公开号：US20180072718A1

  公开（公告）日：2018-03-15

  Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

  公开了化合物的结构式（I），使用这些化合物抑制HPK1活性的方法以及包含这些化合物的药物组合物。这些化合物在治疗、预防或改善与HPK1活性相关的疾病或障碍，如癌症方面具有用处。